A restriction fragment length polymorphism assay that differentiates human N-acetyltransferase-1 (NAT1) alleles

Anal Biochem. 1997 Nov 15;253(2):219-24. doi: 10.1006/abio.1997.2379.


Currently there is much interest in the N-acetyltransferase-1 (NAT1) genetic polymorphism and its relationship to cancer. Previous studies have described methods to distinguish NAT1 alleles through polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) and/or allele-specific amplification. However, these methods detect at most only four of the NAT1 alleles identified in human populations. In this paper we describe a PCR-RFLP-based assay that differentiates among eight human NAT1 alleles (NAT1*3, *4, *5, *10, *11, *14, *15, *16). This method should prove useful in molecular epidemiological studies investigating associations between NAT1 genotype and cancer.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Alleles*
  • Arylamine N-Acetyltransferase / chemistry*
  • Colon / chemistry
  • DNA Primers
  • DNA Restriction Enzymes / chemistry
  • Electrophoresis, Agar Gel
  • Humans
  • Isoenzymes / chemistry*
  • Male
  • Polymerase Chain Reaction / methods
  • Polymorphism, Restriction Fragment Length*
  • Prostate / chemistry


  • DNA Primers
  • Isoenzymes
  • Arylamine N-Acetyltransferase
  • N-acetyltransferase 1
  • DNA Restriction Enzymes